Canadian Market Access Services
Established in 1996, PDCI Market Access is a leading Canadian market access consultancy featuring an experienced reimbursement team and long established relationships with the Common Drug Review (CDR), the Joint Oncology Drug Review (JODR), federal/provincial/territorial (F/P/T) drug plans and major private payers. Our goal is to assist clients in maximizing market access in both the public and private sectors. PDCI’s consulting services are supported by the C-MAP solutions series including the highly respected Canadian Drug Benefit Plan (CDBP) reference guide, an industry standard for more than 10 years.
Our Expertise
PDCI Market Access’ services include:
- Strategic markets access assessments
- Public and private
- Coordination with pricing/PMPRB assessments and strategies
- Reimbursement submissions including:
- Executive summaries
- Clinical summaries
- Budget Impact Analyses
- Cost minimization / cost comparison analyses
- Completion of CDR/payer forms and checklists
- Quality control (to ensure submissions are complete and accurate)
- Assembly and delivery of submissions
- Product listing agreements
- Financial and risk sharing agreements
- Coverage with evidence development
- Liaison with CDR and drug plan managers
- C-MAP Solutions
- Canadian Drug Benefit Plans Reference Guide (CDBP)
- Canadian Drug Claims Database
Our market access team has extensive experience working on national CDR and non-CDR reimbursement submissions (more than 25) for a broad variety of products and therapeutic fields. Recent engagements have included submissions for therapies in:
- Oncology
- Cardiovascular disease
- Diabetes
- Rheumatoid Arthritis & Osteoarthritis
- Urology
- Antiviral (HIV, Hepatitis B)
- Dermatology
- Rare Diseases
- PDCI Market Access develops reimbursement submissions for:
- New chemical entities
- New indications
- New dosage forms and strengths
- Re-submissions
- Manufacturing changes, DIN changes, and product discontinuations
PDCI’s strategic market access assessments identify the opportunities and challenges for optimizing reimbursement of new and existing products in both the public and private sectors. As part of the assessments, PDCI develops recommendations and guidance on the implications of drug plan policies, on which drug plans to submit to, on their submission requirements, and on the timing of the submissions. PDCI Market Access’ listing recommendations success rate consistently exceeds the CDR average.
